New vaccines for RSV and bird flu enter human testing
NCT ID NCT07516418
First seen Apr 09, 2026 · Last updated Jun 23, 2026 · Updated 10 times
Summary
This early-stage trial is testing several new vaccine formulas against two viruses: RSV (a common cause of lung infections) and H5N1 bird flu. About 570 healthy adults aged 18 to 49 will receive one of the vaccines. The main goal is to check safety and see how well the vaccines trigger an immune response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS (RSV) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Site # 036006
RECRUITINGTaringa, Queensland, 4068, Australia
-
Site # 03610004
RECRUITINGSouth Brisbane, Queensland, 4104, Australia
-
Site # 0361001
RECRUITINGHerston, Queensland, 4006, Australia
-
Site # 0361002
RECRUITINGGriffith, Queensland, 4222, Australia
-
Site # 0361003
RECRUITINGMorayfield, Queensland, 4506, Australia
-
Site # 0361005
RECRUITINGSippy Downs, Queensland, 4556, Australia
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RSV and H5 flu vaccines
What this could lead to
If successful, this could lead to safe and effective vaccines against RSV and H5N1 flu, protecting vulnerable populations.
What could go wrong
This is an early Phase 1 trial with only 570 healthy adults. The vaccines may not produce strong immunity or could have side effects. Further trials are needed.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.